IPHA — Innate Pharma SA
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1598599 ·
France
Last close
$1.33
Market Cap
$148.56M
52W High
$2.71
52W Low
$1.17
ADV30
20,927
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 34,726,000 | 6,461,000 | 75,234,000 |
| Dec 2025 | — | — | — | — | 62,719,000 | 28,092,000 | 84,423,000 |
| Jun 2025 | — | — | — | — | 92,937,000 | 53,704,000 | 87,793,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-455,164,000
Inventory
—
Receivables
$4,586,000
ST Investments
$4,435,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,005,000
EBITDA
$-53,309,000
Free Cash Flow
$-34,073,624
Enterprise Value
$163,650,384
Total Cash
$34,310,000
Total Debt
$22,573,000
Shares Out
111,700,347
Trailing EPS
$-0.64
Book Value
$-0.27
ROE
—
ROA
-38.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,787,000 | -53,425,000 | -49,177,000 | 62,719,000 | 84,423,000 | -21,704,000 | -32,559,000 |
| Dec 2024 | 12,621,000 | -51,576,000 | -49,471,000 | 111,059,000 | 102,225,000 | 8,834,000 | -6,896,000 |
| Dec 2023 | 51,901,000 | -12,669,000 | -7,570,000 | 175,187,000 | 123,286,000 | 51,901,000 | -52,755,000 |
| Dec 2022 | 49,580,000 | -16,425,000 | -58,103,000 | 199,295,000 | 145,144,000 | 54,151,000 | -19,155,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.59
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STRO | SUTRO BIOPHARMA, INC. | $148.08M | $8.92 | — |
| IVVD | Invivyd, Inc. | $151.09M | $0.51 | — |
| HUMA | Humacyte, Inc. | $139.18M | $0.50 | — |
| TARA | Protara Therapeutics, Inc. | $137.10M | $2.32 | — |
| IPHYF | Innate Pharma SA | $168.56M | $1.51 | — |
News headlines (Yahoo Finance, 1h cache)
Innate Pharma stock tumbles after phase 1 trial data
2026-11-18 16:53 · Yahoo
Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026
2026-11-18 07:30 · Yahoo
Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026
2026-11-11 06:00 · Yahoo
Innate Pharma Q3 Earnings Call Highlights
2026-11-05 14:14 · Yahoo
Innate Pharma Reports Third Quarter 2026 Business and Financial Update
2026-11-05 06:00 · Yahoo
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
2026-10-27 06:00 · Yahoo
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
2026-10-21 05:00 · Yahoo
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
2026-10-20 05:00 · Yahoo
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
2026-10-08 12:35 · Yahoo
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
2026-09-23 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.